Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189191 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL8085819 | 0.80 | CA1 (0.33) | DPP4DPP8 | |
| SCHEMBL4183223 | 0.80 | CA1 (0.33) | DPP4DPP8 | |
| SCHEMBL6298548 | 0.74 | CA1 (0.39) | — | |
| SCHEMBL16268315 | 0.72 | CA1 (0.37) | — | |
| SCHEMBL6963491 | 0.70 | TRPA1 (0.62) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL21925715 | 0.69 | PSEN1 (0.57) | — | |
| SCHEMBL21925706 | 0.69 | GAA (0.50) | — | |
| SCHEMBL21925707 | 0.69 | GAA (0.50) | — | |
| SCHEMBL21925710 | 0.69 | PSEN1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | DPP4 111/4885DPP8 90/4885DPP9 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.